Patent intelligence · US
US 11344575
Vascular calcification prevention and treatment
Vascular calcification prevention and treatment
Patent details — US 11344575
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 31, 2022
- Expiration
- May 26, 2042
- Applicant
- Summit Innovation Labs LLC
- Claims
- 4
- CPC classes
- A61K, A61K31/07, A61K31/12, A61K31/122
Quick answer
US 11344575 (Vascular calcification prevention and treatment) is held by Summit Innovation Labs LLC. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Summit Innovation Labs LLC
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/07, A61K31/12, A61K31/122, A61K31/353, A61K31/355
More from Summit Innovation Labs LLC
Related pharmaceutical patents in our USPTO index.
-
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 11007171
Treatment and prevention of joint disorders
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9314456
Antibacterial compounds
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Frequently asked questions
What is US patent 11344575?
US 11344575 (Vascular calcification prevention and treatment) is held by Summit Innovation Labs LLC. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11344575?
Summit Innovation Labs LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 11344575 expire?
Our index shows an expiration date of May 26, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.